Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Infect Dis ; 204(7): 1046-53, 2011 Oct 01.
Article in English | MEDLINE | ID: mdl-21881120

ABSTRACT

BACKGROUND: Herd immunity is important in the effectiveness of conjugate polysaccharide vaccines against encapsulated bacteria. A large multicenter study investigated the effect of meningococcal serogroup C conjugate vaccine introduction on the meningococcal population. METHODS: Carried meningococci in individuals aged 15-19 years attending education establishments were investigated before and for 2 years after vaccine introduction. Isolates were characterized by multilocus sequence typing, serogroup, and capsular region genotype and changes in phenotypes and genotypes assessed. RESULTS: A total of 8462 meningococci were isolated from 47 765 participants (17.7%). Serogroup prevalence was similar over the 3 years, except for decreases of 80% for serogroup C and 40% for serogroup 29E. Clonal complexes were associated with particular serogroups and their relative proportions fluctuated, with 12 statistically significant changes (6 up, 6 down). The reduction of ST-11 complex serogroup C meningococci was probably due to vaccine introduction. Reasons for a decrease in serogroup 29E ST-254 meningococci (from 1.8% to 0.7%) and an increase in serogroup B ST-213 complex meningococci (from 6.7% to 10.6%) were less clear. CONCLUSIONS: Natural fluctuations in carried meningococcal genotypes and phenotypes a can be affected by the use of conjugate vaccines, and not all of these changes are anticipatable in advance of vaccine introduction.


Subject(s)
Immunity, Herd/immunology , Meningitis, Meningococcal/prevention & control , Meningococcal Vaccines/administration & dosage , N-Acetylneuraminic Acid/genetics , Neisseria meningitidis/genetics , Neisseria meningitidis/immunology , Adolescent , Adult , Bacterial Capsules/genetics , Bacterial Capsules/metabolism , Carrier State/immunology , Genotype , Humans , Mass Vaccination , Meningitis, Meningococcal/genetics , Meningitis, Meningococcal/immunology , Multilocus Sequence Typing , N-Acetylneuraminic Acid/metabolism , Serotyping , United Kingdom , Young Adult
2.
J Infect Dis ; 197(5): 737-43, 2008 Mar 01.
Article in English | MEDLINE | ID: mdl-18271745

ABSTRACT

BACKGROUND: In 1999, meningococcal serogroup C conjugate (MCC) vaccines were introduced in the United Kingdom for those under 19 years of age. The impact of this intervention on asymptomatic carriage of meningococci was investigated to establish whether serogroup replacement or protection by herd immunity occurred. METHODS: Multicenter surveys of carriage were conducted during vaccine introduction and on 2 successive years, resulting in a total of 48,309 samples, from which 8599 meningococci were isolated and characterized by genotyping and phenotyping. RESULTS: A reduction in serogroup C carriage (rate ratio, 0.19) was observed that lasted at least 2 years with no evidence of serogroup replacement. Vaccine efficacy against carriage was 75%, and vaccination had a disproportionate impact on the carriage of sequence type (ST)-11 complex serogroup C meningococci that (rate ratio, 0.06); these meningococci also exhibited high rates of capsule expression. CONCLUSIONS: The impact of vaccination with MCC vaccine on the prevalence of carriage of group C meningococci was consistent with herd immunity. The high impact on the carriage of ST-11 complex serogroup C could be attributed to high levels of capsule expression. High vaccine efficacy against disease in young children, who were not protected long-term by the schedule initially used, is attributed to the high vaccine efficacy against carriage in older age groups.


Subject(s)
Carrier State/epidemiology , Immunity, Herd/immunology , Meningococcal Infections/epidemiology , Meningococcal Vaccines/immunology , Neisseria meningitidis, Serogroup C/immunology , Neisseria meningitidis , Adolescent , Adult , Cross-Sectional Studies , Humans , Mass Vaccination , Meningococcal Infections/prevention & control , Neisseria meningitidis/classification , Neisseria meningitidis/immunology , Neisseria meningitidis, Serogroup C/pathogenicity , Serotyping , United Kingdom/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...